This guideline describes the approach and expertise needed for the genetic evaluation of
cardiomyopathy. First published in 2009 by the Heart Failure Society of America (HFSA), the …

Background A genetic cause can be identified in 30% of noncompaction cardiomyopathy
patients (NCCM) with clinical features ranging from asymptomatic cardiomyopathy to heart …

Background: Left ventricular noncompaction (LVNC) is the third most common pediatric
cardiomyopathy characterized by a thinned myocardium and prominent trabeculations. Next …

The evidence is increasing that left ventricular noncompaction cardiomyopathy as it is
currently defined does not represent a failure of compaction of pre-existing trabecular …

In the last few decades, many pathogenic or likely pathogenic genetic mutations in over
hundred different genes have been described for non-ischemic, genetic cardiomyopathies …

Notch signaling research dates back to more than one hundred years, beginning with the
identification of the Notch mutant in the fruit fly Drosophila melanogaster. Since then …

Background The left ventricular noncompaction cardiomyopathy (LVNC) is a rare subtype of
cardiomyopathy associated with a high risk of heart failure (HF), thromboembolism …

Notch signaling is an evolutionarily conserved pathway that is widely used for multiple
cellular events during development. Activation of the Notch pathway occurs when the ligand …

Abstract Purpose of Review To discuss the association of left ventricular hypertrabeculation/
noncompaction (LVHT/LVNC/NCCM) with genetic disease and to outline the therapeutic …

Neuroblastoma (NB) is an embryonic malignant tumor that occurs in the sympathetic
nervous system. The treatment results of patients in the high-risk group are poor, and …